Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11011542 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2RAB9AHSD17B10NPC1HTT | |
| SCHEMBL1398174 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2RAB9AHSD17B10NPC1HTT | |
| SCHEMBL5545037 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2RAB9AHSD17B10NPC1HTT | |
| SCHEMBL22286589 | 0.73 | SMN1; SMN2 (0.53) | SMN1; SMN2RAB9AHSD17B10NPC1HTT | |
| SCHEMBL20631846 | 0.69 | HSD17B10 (0.48) | SMN1; SMN2RAB9AHSD17B10NPC1HTT | |
| SCHEMBL4771728 | 0.68 | SMN1; SMN2 (0.44) | SMN1; SMN2RAB9ANPC1MAPTPOLB | |
| SCHEMBL12263499 | 0.68 | ALDH1A1 (0.49) | SMN1; SMN2RAB9AHSD17B10NPC1MAPT | |
| SCHEMBL2705919 | 0.67 | SMN1; SMN2 (0.60) | SMN1; SMN2RAB9AHSD17B10HTTMAPT | |
| SCHEMBL8358314 | 0.67 | HTT (1.00) | SMN1; SMN2HSD17B10HTTPOLBF2 | |
| SCHEMBL4324910 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773082-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11718603-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773082-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | SMN1; SMN2 1988/4885RAB9A 2302/4885HSD17B10 2731/4885 |
| US-11718603-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | SMN1; SMN2 1988/4885RAB9A 2302/4885HSD17B10 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.